title: Regarding: Humar et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010;10:1228–1237.
authors.forename: C
authors.initials: C
authors.lastname: da Cunha-Bang
authors.forename: M
authors.initials: M
authors.lastname: Iversen
authors.forename: S A
authors.initials: SA
authors.lastname: Mortensen
authors.forename: A
authors.initials: A
authors.lastname: Rasmussen
authors.forename: H
authors.initials: H
authors.lastname: Sengeløv
authors.forename: S S
authors.initials: SS
authors.lastname: Sørensen
authors.forename: J
authors.initials: J
authors.lastname: Lundgren
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000517:prevention & control*; D015774:Ganciclovir / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D012307:Risk Factors; D016896:Treatment Outcome; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir